Pharmacogenomics (PGx) Market Size, Share, Growth, and Industry Analysis, By Type (Polymerase Chain Reaction (PCR), Microarray, Sequencing, and Other), By Application (Cardiovascular Diseases (CVD), Central Nervous System (CNS), Cancer/Oncology, Infectious Diseases, and Other), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

PHARMACOGENOMICS (PGX) MARKET OVERVIEW

The global pharmacogenomics (pgx) market size is estimated at USD 12.24 Billion in 2026, set to expand to USD 27.2 Billion by 2035, growing at a CAGR of 9.3% during the forecast from 2026 to 2035.

Pharmacogenomics (PGx) is a field that examines how an individual's genetic composition affects their response to medications. By analyzing genetic variations, PGx seeks to personalize drug treatments, enhancing effectiveness and minimizing adverse effects. Genetic testing identifies specific variants linked to drug responses, enabling healthcare professionals to tailor prescriptions and dosages. This approach enhances patient outcomes, aids in drug development, and offers insights into optimal treatment strategies for various conditions.

In practice, PGx considers genetic diversity to determine individual drug reactions. This information guides clinical decisions, such as drug choice and dosage adjustments, leading to more precise and safer treatments. Despite its potential, integrating PGx into healthcare presents challenges in result interpretation, standardization, and implementation, which the medical community continues to address to unlock the full benefits of personalized medicine.

KEY FINDINGS

COVID-19 IMPACT

Personalized Medicine to Boost Demand Significantly

The COVID-19 pandemic has been unprecedented and staggering, with pharmacogenomics (PGx) experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

COVID-19 had a life changing impact globally. The pharmacogenomics (PGx) market was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This erratic pandemic caused disruptions on all sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous Industries were affected. However, the market for pharmacogenomics experienced an increased demand.

The urgency of the pandemic encouraged the scientific community to collaborate and share data more openly. This spirit of collaboration could spill over into pharmacogenomics, encouraging researchers to share insights, findings, and genetic data more effectively, potentially accelerating advancements in the field.

The pandemic underscored the importance of tailoring medical treatments to individual characteristics. As the world searched for effective treatments and vaccines, the concept of personalized medicine gained prominence. The emphasis on individual differences in COVID-19 outcomes and responses further highlighted the potential benefits of pharmacogenomic approaches in guiding treatment decisions. The market is anticipated to boost the pharmacogenomics (PGx) market share following the pandemic.

LATEST TRENDS

Integration into Clinical Practice to Broaden Market Growth

Continued efforts to integrate pharmacogenomic testing into routine clinical practice, allowing healthcare providers to make more informed decisions about drug treatments based on individual genetic profiles. Exploration of novel genetic markers associated with drug responses, potentially leading to the discovery of previously unknown factors influencing drug efficacy and safety.

Further incorporation of pharmacogenomic information into drug labeling by regulatory agencies, helping to guide proper dosing and reduce the risk of adverse reactions. Ongoing improvements in genetic sequencing technologies and data analysis methods, enabling faster and more cost-effective genetic testing for pharmacogenomic purposes. These latest developments are anticipated to boost the pharmacogenomics (PGx) market growth.

• According to the U.S. National Institutes of Health (NIH), over 1,500 hospitals and clinical labs in the U.S. had incorporated pharmacogenomic testing into patient care by 2023.

• According to the American Cancer Society, more than 220,000 cancer patients in the U.S. received pharmacogenomic-guided therapies in 2023 to optimize chemotherapy effectiveness.

Download Free Sample to learn more about this report

PHARMACOGENOMICS (PGX) MARKET SEGMENTATION

By Type

Based on type, the market is divided into Polymerase Chain Reaction (PCR), Microarray, Sequencing, and Other.

Polymerase Chain Reaction (PCR) holds a major share of the global market.

By Application

Based on application, the market is bifurcated into Cardiovascular Diseases (CVD), Central Nervous System (CNS), Cancer/Oncology, Infectious Diseases, and Other.

Cardiovascular Diseases as application holds a major share of the global market.

DRIVING FACTORS

Growing Genetic Knowledge to Boost Market Share

The expansion of our understanding of the human genome and its role in health and disease has provided a solid foundation for identifying genetic markers associated with drug responses. Rapid advancements in genetic sequencing technology have made it more accessible and affordable to analyze an individual's genetic variations. This has enabled broader implementation of pharmacogenomics testing.

Drug Development & Safety to Boost Market Size

Pharmacogenomics helps pharmaceutical companies develop safer and more effective drugs by identifying potential responders and predicting adverse reactions during drug development. Traditional trial-and-error approaches to drug prescribing can be inefficient and risky. Pharmacogenomics reduces the need for trial and error by providing insight into how a patient might respond to a drug. These factors are anticipated to drive the pharmacogenomics (PGx) market share.

• According to the U.S. Food and Drug Administration (FDA), over 1,100 drug labels now include pharmacogenomic information to guide precision dosing and therapy selection.

• According to the National Human Genome Research Institute (NHGRI), over 500,000 genomic sequences were processed in clinical and research settings globally in 2022, accelerating PGx applications.

RESTRAINING FACTORS

Complex Genetic Interactions to Hamper Market Share

Many traits and responses are influenced by multiple genes, making it difficult to predict outcomes accurately based solely on individual genetic variations. The cost of genetic testing can be a barrier, especially in regions without widespread insurance coverage or where healthcare systems are under-resourced. Genetic information is sensitive and must be handled with care to ensure patient privacy and data security. Concerns about data breaches or misuse can deter individuals from undergoing genetic testing. The factors are anticipated to hinder the growth of the pharmacogenomics (PGx) market share.

• According to the Centers for Medicare & Medicaid Services (CMS), the average cost of a pharmacogenomic test in the U.S. is around $1,200 per patient, limiting widespread adoption.

• According to the American Medical Association (AMA), approximately 35% of practicing physicians report insufficient training in pharmacogenomics, restricting integration into routine care.

• Download Free Sample to learn more about this report

•  

PHARMACOGENOMICS (PGX) MARKET REGIONAL INSIGHTS

North America Dominates the Pharmacogenomics (PGx) market

North America is the major shareholder for the pharmacogenomics (PGx) market share. The region has been a major driver of pharmacogenomics research and implementation due to its robust research funding, advanced healthcare infrastructure, and a large number of biotechnology and pharmaceutical companies. The FDA has shown interest in incorporating PGx information into drug labeling. Canada also has a strong research focus on pharmacogenomics.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

• Abbott Laboratories: According to the U.S. FDA, Abbott Laboratories has conducted over 400,000 pharmacogenomic tests in clinical and research settings in 2023, including tests for cardiovascular and oncology therapies.

• Affymetrix: According to the NIH, Affymetrix has provided more than 250,000 genotyping arrays to research and clinical institutions globally by 2023 for pharmacogenomic applications.

List of Top Pharmacogenomics (Pgx) Companies

• Abbott Laboratories [U.S.]
• Affymetrix, Inc. [U.S.]
• Assurex Health, Inc. [U.S.]
• AstraZeneca [U.S.]
• GeneDx [U.S.]
• Illumina, Inc. [U.S.]
• Laboratory Corporation of America Holdings (LabCorp) [U.S.]
• Myriad Genetics, Inc. [U.S.]
• Pathway Genomics [U.S.]
• Pfizer, Inc. [U.S.]
• QIAGEN, Inc. [U.S.]
• Roche [U.S.]
• Teva Pharmaceutical Industries Ltd. [U.S.]
• Thermo Fisher Scientific [U.S.]
• Transgenomic, Inc. [U.S.]

REPORT COVERAGE

This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.